A prospective, open-label, multicenter, observational, postmarket study of the use of a 15 mg/mL hyaluronic acid dermal filler in the lips

por Philipp-Dormston, Wolfgang G, Hilton, Said, Nathan, Myooran
Publicado 2014

Randomized, Evaluator-Blinded Study Comparing Safety and Effect of Two Hyaluronic Acid Gels for Lips Enhancement

por Hilton, Said, Sattler, Gerhard, Berg, Anna-Karin, Samuelson, Ulf, Wong, Cindy
Publicado 2018

Hyaluronidase injection for the treatment of eyelid edema: a retrospective analysis of 20 patients

por Hilton, Said, Schrumpf, Holger, Buhren, Bettina Alexandra, Bölke, Edwin, Gerber, Peter Arne
Publicado 2014

Treatment of melasma in Caucasian patients using a novel 694-nm Q-switched ruby fractional laser

por Hilton, Said, Heise, Heike, Buhren, Bettina Alexandra, Schrumpf, Holger, Bölke, Edwin, Gerber, Peter Arne
Publicado 2013

Long-term Efficacy and Safety of Liquid AbobotulinumtoxinA Formulation for Moderate-to-Severe Glabellar Lines: A Phase III, Double-Blind, Randomized, Placebo-Controlled and Open-La...

por Kestemont, Philippe, Hilton, Said, Andriopoulos, Bill, Prygova, Inna, Thompson, Catherine, Volteau, Magali, Ascher, Benjamin
Publicado 2021

Hyaluronidase: from clinical applications to molecular and cellular mechanisms

por Buhren, Bettina Alexandra, Schrumpf, Holger, Hoff, Norman-Philipp, Bölke, Edwin, Hilton, Said, Gerber, Peter Arne
Publicado 2016

Liquid AbobotulinumtoxinA: Pooled Data From Two Double-Blind, Randomized, Placebo-Controlled Phase III Studies of Glabellar Line Treatment

por Hilton, Said, Kestemont, Philippe, Sattler, Gerhard, Volteau, Magali, Thompson, Catherine, Andriopoulos, Bill, Prygova, Inna, Berg, Anna-Karin, Ascher, Benjamin
Publicado 2022

Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Gl...

por Ascher, Benjamin, Rzany, Berthold, Kestemont, Philippe, Hilton, Said, Heckmann, Marc, Bodokh, Isaac, Noah, Ernst Magnus, Boineau, Dominique, Kerscher, Martina, Volteau, Magali, Le Berre, Philippe, Picaut, Philippe
Publicado 2019

Significantly Increased Patient Satisfaction Following Liquid Formulation AbobotulinumtoxinA Treatment in Glabellar Lines: FACE-Q Outcomes From a Phase 3 Clinical Trial

por Ascher, Benjamin, Rzany, Berthold, Kestemont, Philippe, Hilton, Said, Heckmann, Marc, Bodokh, Isaac, Noah, Ernst Magnus, Boineau, Dominique, Kerscher, Martina, Volteau, Magali, Le Berre, Philippe, Picaut, Philippe
Publicado 2020

Response to “Facial Line Outcomes (FLO-11) and Facial Line Satisfaction Questionnaire (FLSQ) Meet FDA PRO Guidance”

por Ascher, Benjamin, Rzany, Berthold, Kestemont, Philippe, Hilton, Said, Heckmann, Marc, Bodokh, Isaac, Noah, Ernst Magnus, Boineau, Dominique, Kerscher, Martina, Volteau, Magali, Le Berre, Philippe, Picaut, Philippe
Publicado 2020

Corrigendum to: Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moder...

por Ascher, Benjamin, Rzany, Berthold, Kestemont, Philippe, Hilton, Said, Heckmann, Marc, Bodokh, Isaac, Noah, Ernst Magnus, Boineau, Dominique, Kerscher, Martina, Volteau, Magali, Le Berre, Philippe, Picaut, Philippe
Publicado 2021

PrabotulinumtoxinA vs OnabotulinumtoxinA for the Treatment of Adult Males With Moderate to Severe Glabellar Lines: Post-hoc Analyses of the Phase III Clinical Study Data

por Solish, Nowell, Ascher, Benjamin, Avelar, Rui L, Bertucci, Vince, Bodokh, Isaac, Carruthers, Jean, Cartier, Hugues, Delmar, Henry, Denfeld, Ralf, Heckmann, Marc, Hedén, Per, Hilton, Said, Inglefield, Christopher, Ogilvie, Patricia, Rzany, Berthold-Josef, Sattler, Gerhard, Sebastian, Michael, Swift, Arthur, Trévidic, Patrick
Publicado 2022